Drug Profile
RD 001
Alternative Names: RD 01 - 3SBio; RD 01 long-acting rhEPO - 3SBio; RD001; RD001 Long-acting EPOLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator 3SBio
- Class Antianaemics; Erythropoietins; Macromolecular substances
- Mechanism of Action Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Anaemia
Most Recent Events
- 24 Aug 2022 3SBio plans an IND application for perioperative Anaemia in orthopedic surgery
- 24 Aug 2022 3SBio plans a phase III clinical trial for Anaemia in chronic kidney disorder patients
- 26 Jul 2022 RD 001 is still in phase II trials for Anaemia in China (unspecified route) (3SBio pipeline, July 2022)